Abnormal Corpus Cavernosum Morphology C4022009
An abnormality in the spongy tissue that allows erections. It can affect sexual function and may require medical evaluation.
Key facts at a glance
- ICD-10
- N94.9
- ICD-11
- GA00.0
- Body system
- reproductive
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Severe penile pain
Intense, sharp pain in the penis during erection or sexual activity that significantly impacts quality of life.
Seek immediate care if experiencing severe sudden-onset penile pain, as it may indicate a serious complication.
Urinary difficulty
Painful or difficult urination due to involvement of structures near the urethra.
Seek immediate care if experiencing inability to urinate or blood in urine.
Erectile dysfunction
(reproductive)Inability to achieve or maintain sufficient erection for satisfactory sexual activity.
Frequency: 70-85% of patients
Penile curvature
(reproductive)Abnormal bending or curvature of the penis during erection, often noticeable during intercourse.
Frequency: 60-75% of patients
Penile pain during erection
(reproductive)Discomfort or pain in the penis when it becomes erect, ranging from mild to severe.
Frequency: 40-55% of patients
Penile indentation
(reproductive)Visible dent, depression, or hourglass shape in the penile shaft when erect.
Frequency: 35-50% of patients
Psychological distress
(constitutional)Feelings of anxiety, embarrassment, or depression related to sexual performance and body image concerns.
Frequency: 45-60% of patients
Reduced penile sensitivity
(reproductive)Decreased sensation or numbness in the penis, affecting sexual pleasure.
Frequency: 15-25% of patients
Ejaculatory dysfunction
(reproductive)Difficulty with ejaculation, including premature, delayed, or painful ejaculation.
Frequency: 20-30% of patients
Penile shortening
(reproductive)Perceived or actual reduction in penile length, particularly when erect.
Frequency: 15-25% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Neuroimaging Follow-up
Regular MRI or CT scans to monitor the corpus callosum abnormality over time and assess for any progression or associated conditions that may develop.
Neurological Rehabilitation
Targeted physical therapy focusing on motor coordination, balance, and functional movement patterns to address any neurological deficits associated with the abnormality.
Additional treatment options
Neuropsychological Support
Comprehensive neuropsychological evaluation and counseling to address cognitive impacts, learning difficulties, or behavioral changes that may be associated with the condition.
psychologicalEducational Accommodations
Implementation of individualized education plans and learning strategies tailored to any specific challenges related to interhemispheric communication.
lifestyleOccupational Therapy
Skill-building therapy focusing on daily living activities, fine motor skills, and sensory integration to maximize functional independence.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Corpus Cavernosum Morphology C4022009?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
American Urological Association. Erectile Dysfunction: AUA Guideline on the Management of Erectile Dysfunction. Journal of Urology. 2018.
European Association of Urology. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Peyronie's Disease. 2022.
Shindel AW, Quayle SN, Sadeghi-Nejad H. Erectile Dysfunction in Primary Care: A Review. Current Urology Reports. 2020.
Levine LA, Kloner RA. Understanding Peyronie's Disease: Pathophysiology and Treatment Options. Journal of Sexual Medicine. 2021.
Walsh PC, Retik AB, Vaughan ED, Wein AJ. Campbell-Walsh Urology. 12th Edition. Elsevier. 2020.
Rosen RC, Giuliano F, Carson CC. Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Meta-Analysis of Randomized Controlled Trials. European Urology. 2019.
Hellstrom WJ, Gittelman M, Jarow J. Collagenase Clostridium Histolyticum for Peyronie's Disease: Phase 3 Clinical Trials. Journal of Urology. 2018.
International Society for Sexual Medicine. Consensus Statement on Penile Morphology Abnormalities. Journal of Sexual Medicine. 2021.
American Sexual Health Association. Consensus Conference on Male Sexual Health and Penile Abnormalities. 2019.
Medication Comparisons
Compare medications used to treat Abnormal Corpus Cavernosum Morphology C4022009. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy